Last reviewed · How we verify

Cisplatin / Carboplatin，Gemcitabine，Cindilimab

People's Hospital of Quzhou · FDA-approved active Small molecule

Cisplatin / Carboplatin，Gemcitabine，Cindilimab is a Combination chemotherapy with immune checkpoint inhibitor Small molecule drug developed by People's Hospital of Quzhou. It is currently FDA-approved for Non-small cell lung cancer, Other solid tumors (specific indications not fully characterized in available literature).

This is a combination regimen of platinum-based chemotherapy agents (cisplatin/carboplatin) and a nucleoside analog (gemcitabine), plus an anti-PD-L1 monoclonal antibody (cindilimab) that together kill cancer cells through DNA damage and immune checkpoint inhibition.

This is a combination regimen of platinum-based chemotherapy agents (cisplatin/carboplatin) and a nucleoside analog (gemcitabine), plus an anti-PD-L1 monoclonal antibody (cindilimab) that together kill cancer cells through DNA damage and immune checkpoint inhibition. Used for Non-small cell lung cancer, Other solid tumors (specific indications not fully characterized in available literature).

At a glance

Generic nameCisplatin / Carboplatin，Gemcitabine，Cindilimab
SponsorPeople's Hospital of Quzhou
Drug classCombination chemotherapy with immune checkpoint inhibitor
TargetDNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Cisplatin and carboplatin are platinum compounds that cross-link DNA and induce apoptosis in rapidly dividing cells. Gemcitabine is a deoxycytidine analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination. Cindilimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby restoring anti-tumor immune responses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cisplatin / Carboplatin，Gemcitabine，Cindilimab

What is Cisplatin / Carboplatin，Gemcitabine，Cindilimab?

Cisplatin / Carboplatin，Gemcitabine，Cindilimab is a Combination chemotherapy with immune checkpoint inhibitor drug developed by People's Hospital of Quzhou, indicated for Non-small cell lung cancer, Other solid tumors (specific indications not fully characterized in available literature).

How does Cisplatin / Carboplatin，Gemcitabine，Cindilimab work?

This is a combination regimen of platinum-based chemotherapy agents (cisplatin/carboplatin) and a nucleoside analog (gemcitabine), plus an anti-PD-L1 monoclonal antibody (cindilimab) that together kill cancer cells through DNA damage and immune checkpoint inhibition.

What is Cisplatin / Carboplatin，Gemcitabine，Cindilimab used for?

Cisplatin / Carboplatin，Gemcitabine，Cindilimab is indicated for Non-small cell lung cancer, Other solid tumors (specific indications not fully characterized in available literature).

Who makes Cisplatin / Carboplatin，Gemcitabine，Cindilimab?

Cisplatin / Carboplatin，Gemcitabine，Cindilimab is developed and marketed by People's Hospital of Quzhou (see full People's Hospital of Quzhou pipeline at /company/people-s-hospital-of-quzhou).

What drug class is Cisplatin / Carboplatin，Gemcitabine，Cindilimab in?

Cisplatin / Carboplatin，Gemcitabine，Cindilimab belongs to the Combination chemotherapy with immune checkpoint inhibitor class. See all Combination chemotherapy with immune checkpoint inhibitor drugs at /class/combination-chemotherapy-with-immune-checkpoint-inhibitor.

What development phase is Cisplatin / Carboplatin，Gemcitabine，Cindilimab in?

Cisplatin / Carboplatin，Gemcitabine，Cindilimab is FDA-approved (marketed).

What are the side effects of Cisplatin / Carboplatin，Gemcitabine，Cindilimab?

Common side effects of Cisplatin / Carboplatin，Gemcitabine，Cindilimab include Myelosuppression (neutropenia, thrombocytopenia, anemia), Nausea and vomiting, Nephrotoxicity, Neuropathy, Immune-related adverse events (from cindilimab).

What does Cisplatin / Carboplatin，Gemcitabine，Cindilimab target?

Cisplatin / Carboplatin，Gemcitabine，Cindilimab targets DNA (platinum agents, gemcitabine); PD-L1 (cindilimab) and is a Combination chemotherapy with immune checkpoint inhibitor.

Related